Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors

Laboratory Investigation

Volumn 87, Issue 10, 2007, Pages 1029-1041

  Lasota, Jerzy ^a   Vel Dobosz, Anna Jerzak ^b   Wasag, Bartosz ^c   Wozniak, Agnieszka ^c   Kraszewska, Ewa ^d   Michej, Wanda ^b   Ptaszynski, Konrad ^b   Rutkowski, Piotr ^b   Sarlomo Rikala, Maarit ^e   Steigen, Sonja E ^f   Schneider Stock, Regine ^g   Stachura, Jerzy ^h   Chosia, Maria ⁱ   Ogun, Gabriel ^j   Ruka, Wlodzimierz ^b   Siedlecki, Janusz A ^b   Miettinen, Markku ^a  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^g OTTO VON GUERICKE UNIVERSITY   (Germany)

^h JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

ⁱ POMERANIAN MEDICAL UNIVERSITY   (Poland)

^j UNIVERSITY OF IBADAN   (Nigeria)

more..

Author keywords

FISH; GIST; KIT; LOH; Mutation; SNP

Indexed keywords

IMATINIB;

ADULT; AGED; ALLELE; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CENTROMERE; CHROMOSOME 4; CHROMOSOME DUPLICATION; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; HETEROZYGOSITY; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MALE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MITOSIS RATE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SARCOMA; SURVIVAL TIME; TUMOR GROWTH; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; EXONS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HOMOZYGOTE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RISK ASSESSMENT;

EID: 34548788543     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700628     Document Type: Article

References (39)

1. Miettinen M, Lasota J. Pathology and prognosis of gastrointestinal stromal tumors at different sites. Semin in Diagn Pathol 2006;23:70-83.
2. Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;153:1259-1269.
3. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580.
4. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-710.
5. Pawson T. Regulation and targets of receptor tyrosine kinases. Eur J Cancer 2002;38(Suppl 5):S3-S10.
6. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors (GISTs) of the stomach - a clinicopathologic, immunohistochemical and molecular genetic study of 1756 cases with long-term follow-up. Am J Surg Pathol 2005;29:52-68.
7. Wardelmann E, Losen I, Hans V, et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 2003;106:887-895.
8. Martin J, Poveda J, Llombart-Bosch A, et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 2005;23:6190-6198.
9. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
10. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813-3825.
11. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumors. Eur J Cancer 2006;42:1093-1103.
12. Ernst SI, Hubbs AE, Przygodzki RM, et al. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998;78:1633-1636.
13. Li QS, O'Leary TJ, Sobin LH, et al. Analysis of KIT mutation and protein expression in fine needle aspirates of gastrointestinal stromal/smooth muscle tumors. Acta Cytol 2000;44:981-986.
14. Corless CL, McGreevey L, Haley A, et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002;160:1567-1572.
15. Emile JF, Theou N, Tabone S, et al. Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol 2004;2:597-605.
16. Hou YY, Tan YS, Sun MH, et al. C-kit gene mutation in gastrointestinal stromal tumors. World J Gastroenterol 2004;10:1310-1314.
17. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistence to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroentereology 2005;128:270-279.
18. Cho S, Kitadai Y, Yoshida S, et al. Deletion of the KIT gene is associated with liver metastasis and poor prognosis in patients with gastrointestinal stromal tumor in the stomach. Int J Cancer 2006;28:1361-1367.
19. Kikuchi H, Yamashita K, Kawabata T, et al. Immunohistochemical and genetic features of gastric and metastatic liver gastrointestinal stromal tumors: sequential analyses. Cancer Sci 2006;97:127-132.
20. Miettinen M, Makhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors (GISTs) of the jejunum and ileum: a clinicopathologic, immunohistochemical and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006;30:477-489.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;90:205-216.
22. Lasota J, Wozniak A, Sarlomo-Rikala M, et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of two hundred cases. Am J Pathol 2000;157:1091-1095.
23. Canzian F, Salovaara R, Hemminki A, et al. Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res 1996;56:3331-3337.
24. Debiec-Rychter M, Lasota J, Sarlomo-Rikala M, et al. Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation. Cancer Genet Cytogenet 2001;128:24-30.
25. Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000;156:791-795.
26. Gunawan B, Bergmann F, Hoer J, et al. Biological and clinical significance of cytogenetic abnormalities in low-risk and high-risk gastrointestinal stromal tumors. Human Pathol 2002;33:316-321.
27. El Rifie W, Sarlomo-Rikala M, Andersson LC, et al. DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res 2000;60:3899-3903.
28. Steigen SE, Eide TJ, Wasag B, et al. Mutations in gastrointestinal stromal tumors - a population based study from northern Norway. APMIS 2007;115:69-72.
29. Agaimy A, Wunsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007;31:113-120.
30. O'Riain C, Corless CL, Heinrich MC, et al. Gastrointestinal stromal tumors. Insights from a new familial GIST kindred with unusual genetic and pathologic features. Am J Surg Pathol 2005;29:1680-1683.
31. Antonescu CR, Sommer G, Sarran L, et al. Association of KIT exon 9 mutation with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003;9:3329-3337.
32. Lasota J, Dansonka-Mieszkowska A, Stachura T, et al. Gastrointestinal stromal tumors with internal tandem duplications in 3′ end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod Pathol 2003;16:1257-1264.
33. Daum O, Grossmann P, Vanecek T, et al. Diagnostic morphological features of PDGFRA-mutated gastrointestinal stromal tumors: molecular genetic and histologic analysis of 60 cases of gastric gastrointestinal stromal tumors. Annals of Diagnostic Pathology 2007;11:27-33.
34. Kim HJ, Lim SJ, Park K, et al. Multiple gastrointestinal stromal tumors with a germline c-kit mutation. Pathol Int 2005;55:655-659.
35. Lasota J, Miettinen M. A new familial GIST identified. Am J Surg Pathol 2006;30:1342.
36. Joensuu H, Puputti M, Sihto H, et al. Amplification of genes encoding KIT PDGFRα and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. J Pathol 2005;207:224-231.
37. Puputti M, Tynninen O, Sihto H, et al. Amplification of KIT PDGFRA VEGFR2 and EGFR in Gliomas. Mol Cancer Res 2006;4:927-934.
38. McIntyre A, Summersgill B, Grygalewicz B, et al. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res 2005;65:8085-8089.
39. Tabone S, Theou N, Wozniak A, et al. KIT overexpression and amplification in gastrointestinal stromal tumors (GISTs). Biochim Biophys Acta 2005;1741:165-172.